Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome
- 1 February 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (2), 600
- https://doi.org/10.1200/jco.1999.17.2.600
Abstract
PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular dosing. PATIENTS AND METHODS: A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome. Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population. RESULTS: Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P ≥ .72 for all pairwise comparisons). Control of stool frequency was similar in all treatment groups. Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing. Treatment was well tolerated by patients in all four groups. CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved.Keywords
This publication has 16 references indexed in Scilit:
- An analysis of 8305 cases of carcinoid tumorsCancer, 2000
- Carcinoid tumoursPublished by Oxford University Press (OUP) ,1997
- Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patientsMetabolism, 1996
- Carcinoid Tumors: Development of Our KnowledgeWorld Journal of Surgery, 1996
- The epidemiology of carcinoid tumours in England and ScotlandBritish Journal of Cancer, 1994
- Metastatic Carcinoid Tumors and the Malignant Carcinoid SyndromeAnnals of the New York Academy of Sciences, 1994
- Effects of Sandostatin on Neuroendocrine Tumours of the Gastrointestinal SystemPublished by Springer Science and Business Media LLC ,1993
- Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the GutAnnals of Internal Medicine, 1989
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- Carcinoid TumorsAn analysis of 2837 casesCancer, 1975